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Abstract. This study elucidates the physical properties of sono-crystallised micro/nano-sized
acetaminophen/paracetamol (PMOL) and monitors its possible transformation from polymor-
phic form I (monoclinic) to form II (orthorhombic). Hydrophilic Plasdone® S630 copovidone
(S630), N-vinyl-2-pyrrolidone and vinyl acetate copolymer, and methacrylate-based cationic
copolymer, Eudragit® EPO (EPO), were used as polymeric carriers to prepare drug/polymer
binary mixtures. Commercially available PMOL was crystallised under ultra sound sonication to
produce micro/nano-sized (0.2–10 microns) crystals in monoclinic form. Homogeneous binary
blends of drug-polymer mixtures at various drug concentrations were obtained via a thorough
mixing. The analysis conducted via the single X-ray crystallography determined the detailed
structure of the crystallised PMOL in its monoclinic form. The solid state and the morphology
analyses of the PMOL in the binary blends evaluated via differential scanning calorimetry
(DSC), modulated temperature DSC (MTDSC), scanning electron microscopy (SEM) and hot
stage microscopy (HSM) revealed the crystalline existence of the drug within the amorphous
polymeric matrices. The application of temperature controlled X-ray diffraction (VTXRPD) to
study the polymorphismof PMOL showed that themost stable form I (monoclinic) was altered to
its less stable form II (orthorhombic) at high temperature (>112°C) in the binary blends
regardless of the drug amount. Thus, VTXRD was used as a useful tool to monitor polymorphic
transformations of crystalline drug (e.g. PMOL) to assess their thermal stability in terms of
pharmaceutical product development and research.
KEY WORDS: monoclinic; nano-sized crystals; orthorhombic; sono-crystallisation; variable temperature
XRPD.
INTRODUCTION
‘Polymorphism’ generally referred as the ability of a
crystalline material to exist in two or more crystalline forms is
considered a pivotal part of the crystallisation processes (1, 2). A
metastable state of the polymorphs which may not necessarily be
obtained easily can accelerate physicochemical and mechanical
properties of a drug substance compared to that of the marketed
or its naturally occurred counter stable form (1). Moreover,
different polymorphic forms may result on signiﬁcant changes in
the solubility and dissolution rates of an active entity (1). By
deﬁnition, crystalline polymorphs are those crystal lattice inwhich
the crystalline components represent different and discrete
phases from a thermodynamic viewpoint.
The current demand for micro/nano-material various appli-
cations in medical and pharmaceutical industry especially in drug
delivery has triggered the research in organic crystal engineering
and development (3, 4). Crystal engineering is particularly
important for the development of pharmaceutical molecules in
the context of improved drug delivery or bio-labelling/bio-sensing
(5, 6). Micronising of molecular crystals has also become an
emerging approach mainly in the development of different water
insoluble drugs by enhancing the dissolution rates (7, 8). Interest-
ingly, despite the unique physicochemical properties of the
molecular crystals, majority of the reported studies have primarily
focused on the solubility aspects whilst other applications such as
mechanical properties have been relatively unexplored in pharma-
ceutical research and developments. There is an immense need to
explore the potential of crystal engineering to enhance the physical/
mechanical properties of drug candidates (e.g. paracetamol). It has
been seen that the implementation of sono-crystallization—the use
of ultrasound to facilitate crystallisation (9)—can produce micro to
1 Pharmaceutics Research Laboratory, School of Life Sciences,
University of Sussex, Arundel Building, Falmer, Brighton BN1
9QG, UK.
2Drug Applied Research Center and Faculty of Pharmacy, Tabriz
University of Medical Sciences, Tabriz, Iran.
3 To whom correspondence should be addressed. (e-mail:
M.Maniruzzaman@sussex.ac.uk; A.Nokhodchi@sussex.ac.uk)
AAPS PharmSciTech (# 2016)
DOI: 10.1208/s12249-016-0596-x
1530-9932/16/0000-0001/0 # 2016 The Author(s). This article is published with open access at Springerlink.com
nano-meter-sized crystals with improved mechanical properties.
Moreover, it will be of signiﬁcant interest in crystal engineering and
science to monitor the stability of the polymorphic forms or the
transformations of these sono-crystallised micro/nano-sized drug
crystals.
Paracetamol (PMOL) exists as a white crystalline powder is
used as analgesic pain reliever (10). It is sparingly soluble in water
(∼12.78 mg/ml), and it exhibits multi-polymorphic forms such as
monoclinic, orthorhombic and a rarely occurred meta or less
stable form with less stability and melting points (11, 12). These
forms are also known as forms I, II and III, respectively. Thus,
PMOL serves an excellent model drug candidate to study the
effects of manufacturing techniques and the subsequent conver-
sions on its crystal forms (1, 11). Also, the glass transition
temperature of PMOL at 25°C makes it an interesting system
(11). The crystallisation technique and process to engineer the
micronised (or nano-sized) crystals of PMOL may provide a
useful mean for the characterisation and evaluations of the
physico-chemical properties of the pharmaceutical dosage forms.
Temperature variable X-ray powder diffraction (VTXRPD)
analysis has already been used as a powerful tool to characterise
the polymorphism of pharmaceutical crystalline drugs and their
stability as a function of increasing temperature (13, 14). In one of
our previous study, the effect of temperature on the transforma-
tion of PMOL crystal was studied by implementing VTXRD as a
predictive tool during the HME processing (15). However, the
effect of crystal engineering, e.g. sono-crystallisation on the
polymorphic stability of the PMOL crystals, was not studied.
We report a new case to fabricate micro/nano-sized
PMOL crystals and monitor its polymorphic transformation
upon heating using a VTXRD method to assess the stability
of the manufactured crystals alone or in combination with
either hydrophilic vinylpyrrolidone-vinyl acetate polymers
(S630) or methacrylate copolymers (EPO).
MATERIALS AND METHOD
Materials
The drug paracetamol (PMOL) was bought from Sigma-
Aldrich (Gillingham, UK). Vinylpyrrolidone-vinyl acetate,
Plasdone S630 (S630) and Eudragit EPO (EPO) were
donated by ISP (Germany) and Evonik Industries (Ger-
many), respectively, and were used as received.
Calculations of Hansen Solubility Parameters (δ)
Solubility parameters (16) were determined for the
assessment of the possible miscibility of the drug with two
polymers and were determined by utilising the Hoftyzer and
van Krevelen method (17) as shown in the equation below:
δ2 ¼ δ2d þ δ2p þ δ2h ð1Þ
where
δd ¼ ΣFdiVi ; δp ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ΣF2pi
q
Vi
; δh ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ΣEhi
Vi
r
i = group contributions in the drug/polymer molecules, δ =
solubility parameters, Fdi = dispersion energy, F
2
pi =molar
polarization energy, Ehi = hydrogen bonding and V =molar
volume.
Preparation of Paracetamol Crystals and Drug-Polymer
Binary Mixtures
Excessive amount of PMOL (500 mg) was dissolved in
minimal amount of ethanol (3 ml) and stirred with a magnetic
stirrer in ambient until all PMOL got completely dissolved in
the solvent making the solution completely transparent. The
PMOL solution was then poured into n-hexane solution
(200 ml) kept in an ultra-sonic bath at 50-kHz frequency
(Fisher Chemicals, UK) until sono-crystallised PMOL parti-
cles precipitated completely. The precipitation of crystallised
PMOL was then isolated by using a vacuum pump and
washed with additional n-hexane and kept in oven at 50°C
overnight to obtain dry PMOL crystals.
Manufactured crystallised PMOL was mixed with two
hydrophilic polymers to investigate the possible drug/polymer
miscibility and hence any interactions that may lead to a
possible polymorphic transformation. The loadings of PMOL
in the formulations were kept between 30 and 60% (w/w) as
shown in Table I. Appropriate amount of drug and polymer
was mixed in a mortar and pestle prior to a thorough blending
in a TF2 Turbula mixture (Switzerland) for 10 min in order to
obtain a homogenous drug/polymer binary mixture.
Microscopic Imaging
The surface properties of the bulk drug and the drug/
polymer mixtures were evaluated by Stereo-Scan S360 SEM
(Cambridge Instruments, UK) at the accelerating voltage of
20 kV. For this purpose of the study, the samples were
mounted on an aluminium stub using adhesive carbon tape
and were sputter coated with gold. A Leica high-
magniﬁcation microscope was used to take photographs of
the crystalline PMOL particles for the comparison with the
commercial drug. The average particle size was determined
by investigating an area having at least 200–500 particles of
the sono-crystallised PMOL and measuring the diameter by
using the scale bar presented in the images.
Thermal Analysis Via DSC and MTDSC
The solid state of the bulk drug, bulk polymers and
mixtures of drug/polymers in different ratios was studied by
using a differential scanning calorimeter (DSC) 823e
manufactured by Mettler-Toledo (Greifensee, Switzerland).
Table I. Formulation Compositions of PMOL and Percentage
Crystallinity of PMOL in Various Drug/Polymer Binary Blends
Name F1 F2 F3 F4 F5 F6
Paracetamol 30 50 60 30 50 60
Eudragit EPO 70 50 40
Plasdone S630 70 50 40
Crystallinity (%) 28.2 48.2 58.3 27.9 47.7 58.7
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Approximately 3–5 mg of samples was weighed and taken in
a sealed aluminium pans and heated at 1–10°C/min variable
heating rates at the range of 0—220°C under an inert
environment (nitrogen). The lids were pierced to allow the
release of the excessive pressure generated upon heating. The
experimental set-up for conducting the modulated tempera-
ture differential scanning calorimetry (MTDSC) was temper-
ature 20 to 150°C (pulse width of 15–30 s), heating rate of
1°C/min and the pulse height at 1–2°C.
HSM Analysis
The thermal analysis of sono-crystallised drug in the
formulations was studied using a hot stage microscopy
(Olympus BX60 microscope, Olympus Corp., USA) with
Insight QE camera (Diagnostic Instruments, USA) that was
used to monitor the sample transitions. A FP82HT hot stage
controlled by a FP 90 central processor (Mettler Toledo,
Columbus, OH) was used to maintain temperatures between
20 and 250°C while a spot advance software (Diagnostic
Instruments, Inc.) was utilised to capture the images.
Single X-Ray Crystallographic Study
An appropriately selected single crystal of sono-
crystallised PMOL was placed onto a 0.1-mm tip of a glass
ﬁbre and placed on a Bruker Apex II CCD diffractometer
(Germany). The data collection was performed at 173(2) K
using MoKα radiation while the SAINT processing program
was utilised for data processing and manipulations. The
PMOL crystal structure was extracted and reﬁned by using
Bruker SHELXTL.
VTXRPD Analysis
The crystallinity and the possible polymorphic transfor-
mation of PMOL were evaluated by using a Bruker D8
Advance (Germany) in theta-theta reﬂection mode with
copper anode. A parallel beam Goebel mirror with 0.2-mm
exit slit and LynxEye sensitive detector opening at 3 degrees
with 176 active channels was used. Each sample was scanned
from 2 to 40 2θ with a step size of 0.02 2θ. An Anton Paar
TTK450 non-ambient sample chamber was used to achieve
the variable temperature with a heating rate of 0.2°C/s. Data
collection and interpretations were performed using
DiffracPlus and the the EVAV.16 program, respectively (18).
RESULTS AND DISCUSSION
Drug/Polymer Miscibility (Hansen Solubility Parameters)
The drug/polymer miscibility was estimated by correlat-
ing the energy of mixing from inter- and intra-molecular
interactions of the materials used (drug and polymers) (19).
For this purpose, the Hansen parameters (δ) calculated based
on the structural orientation of the component informs that
the drug-polymers with similar δ values used in a system are
likely to interact with each other as matter of being miscible.
It has widely been accepted that two compounds are
generally treated miscible when Δδ is less than 7 MPa1/2
(17, 20). The higher values of Δδ (>7 MPa1/2) between a drug/
polymer pair generally indicate an immiscibility.
It has been seen in the literature that the solubility
parameters provide a general indication of two components
which are generally a drug and a polymer to develop solid
drug-polymer mixtures in which drug particles can be
dispersed in the polymer matrices. The estimated δ values
of PMOL, S630 and EPO are summarised in Table II, where
it can be seen that the Δδ of both hydrophilic polymeric
carriers and the drug used in the binary systems are less than
7 MPa1/2. This indicates that PMOL is miscible with both
S630 and eudragit grade copolymer EPO. The Δδ values
observed in both drug/polymer binary systems are less than
7 MPa1/2. Therefore, based on the theoretical calculation, it
can be claimed that both polymers are expected to be
miscible with the drug used in the binary systems.
Microscopic Imaging
The surface properties of the bulk API and the drug/
polymer binary mixtures studied by SEM are shown in Fig. 1a.
The micrographs of crystallised PMOL exhibited octahedral
shaped crystals representing monoclinic form (2). Similarly,
the commercial PMOL revealed similar characteristic mono-
clinic crystalline structures (data not shown). The surface
analysis conducted via SEM of all binary mixtures also
showed the presence of monoclinic form of PMOL in nano-
to micro-scale with both S630 and EPO polymers in all
formulations. These ﬁndings indicated the presence of
crystalline PMOL in its original monoclinic form without
any transformations yet. Interestingly, the photographs cap-
tured via a High-Magniﬁcation Leica microscope of both
commercial PMOL (un-micronized) and the sono-crystallised
PMOL (micronized) revealed signiﬁcant size differences as
shown in Fig. 1b. The average particle size of the commercial
PMOL crystals ranged from 50 to 250 μm (by investigation at
Table II. Hansen Solubility Parameters of PMOL and Polymers Used in the Binary Blends
Sample δd δp δv δh δ Δδ
(MPa1/2) (MPa1/2) (MPa1/2) (MPa1/2) (MPa1/2)
Paracetamol 19.67 7.93 21.20 13.96 25.39 –
Plasdone S630 15.14 0.45 15.15 12.18 19.43 5.96
Eudragit EPO 17.89 0.65 17.89 6.08 18.90 6.49
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Fig. 1. a SEM images of the micro-crystalline PMOL and the formulations; b microscopic photographs of commercial PMOL and sono-
crysallised PMOL (micro-nano sized)
Fig. 2. a DSC thermal transitions of bulk PMOL and polymers. b DSC thermograms of
PMOL/EPO binary systems
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least 200–500 particles) while the sono-crystallised PMOL
(PMOL) showed a particle size ranging from 0.2 to 10 μm. This
was also evident in all drug/polymer binary mixtures using two
different polymers. The optimised sono-crystallisation approach
produced nano-sized crystals of PMOL which may prove
advantageous to enhance the physico-mechanical properties of
the very poorly compactible actives such as PMOL. Similar
studies have been reported elsewhere (21).
Table III. Thermal Transition Summary of Bulk Drug, Polymers and the Drug/Polymer Binary Formulations
Formulations Glass transition/ enthalpy Melting endotherms/ enthalpy
(°C/ΔH, Jg−1) (°C/ΔH, Jg−1)
PMOL 24.55 169.1/137.06
S630 105.5 N/A
EPO 48.56 N/A
F1 45.90 143.31/20.49
F2 44.09 148.48/23.83
F3 41.67 151.47/33.81
F4 52.85 137.04/13.27
F5 105.80 131.30/7.20
F6 102.25 123.35/5.50
Fig. 3. HSM images of PMOL and PMOL loaded formulations
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Thermal Analysis
The thermal transitions of the bulk drug, polymers and
the formulations were analysed by DSC. The DSC thermo-
grams of crystallised PMOL showed a sharp transition due to
its melting at 169.1°C with an enthalpy ΔH 137.00 J/g. This
transition represents the polymorphic form I (monoclinic)
(Fig. 2a) and complements the ﬁndings from the literature (2,
10, 11). In the case of both polymers, a modulated temper-
ature DSC was used as the conventional DSC thermogram
showed enthalpy relaxation peak that overlapped with the
glass transition temperatures (Tgs) of the polymers. For
methacrylate EPO, an endothermic thermal step change was
observed at 48.38°C whilst for S630 at 105.51°C. Both
endothermic thermal events correspond to the Tg of the
respective amorphous copolymers.
The DSC thermograms of the drug/EPO mixtures (F1-
F3) (Table III) showed endothermic thermal transitions at
143–151.57°C at various drug loadings (30–50% w/w ratios)
(Fig. 2b). Similarly, all formulations with S630 showed two
endothermic thermal transitions as shown in Table III: one
corresponding to the melting of the drug at higher end (123–
137°C) and another one at lower end due to the Tgs of the
amorphous polymer. From the results, it is quite evident that
the shifted melting transitions have become broader com-
pared to those of pure drug indicating the decrease in the
crystallinity of PMOL (12). Moreover, this could also possibly
be attributed to the drug-polymer interactions in the binary
blends. However, the study of volume fraction of PMOL in
the formulations has played a pivotal role on the melting
temperature of the drug with EPO. The increase in the drug
concentration in the formulations resulted in the increase in
the melting endotherms (data not shown). In contrast, a
different result was observed with the S630 polymer, due to
the nature of the polymer and possible drug/polymer
interaction strength.
Fragility indicates the degree of viscosity and relaxation
time change of a material at its glassy state. The fragility
index (m) of strong glasses has typical values of m < 100 and
weak glasses 100 <m < 200 (11). In this study, the activation
enthalpy and thus the fragility index (m) at the Tgs were
estimated by using DSC as expressed in the following
Fig. 4. Single X-ray crystallographic image of PMOL-monoclinic form (stacking)
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equations: where m = fragility index, Ea = activation energy
and R = gas constant (22, 23).
lnqþ ¼ −
Ea
RT
ð2Þ
m ¼ Ea
.
2:303  R  Tgm
  ð3Þ
By using Eq. (3), it has been calculated that the
crystallised PMOL has a fragility index of 83.8, which is less
than that found by Qi et al. 86.7 (11). It simply indicates that
the PMOL system in this study is a stronger glass compared
to that of previously studied amorphous paracetamol. Simi-
larly, the m values calculated for PMOL in PMOL/S630 (F4-
F6) formulations are between 97.7 and 188.9 for 30–60%
PMOL loadings which indicates that PMOL is neither same
as amorphous paracetamol nor crystalline paracetamol form
I. Rather PMOL in the formulations upon heating represents
more fragile systems (e.g. form II) may be stuck together by
weak van der Waals forces (11, 23).
Thermal analysis conducted via HSM determined the
thermal transitions due to the melting of crystalline PMOL
within the polymer matrices as a function of heating. Various
images of both the bulk drug and drug/polymer binary
mixtures taken using HSM are depicted in Fig. 3. As
expected, the bulk drug exhibited no thermal changes up to
its melting (168°C) complementing the results obtained from
the DSC. In the DSC results, there were no thermal events
that occurred until about 169.10°C when it melted. Similar to
the DSC ﬁndings, the drug/polymer binary mixtures displayed
minimal drug melting at the heating temperature that reaches
130–140°C and afterward presented a complete melting of the
drug crystals present in the polymer matrices (Fig. 3).
Variable X-Ray Powder Diffraction (VTXRPD) Studies
The variable temperature effect on the alteration in the
crystal structure of sono-crystallised PMOL was monitored by
VTXRPD approach. The results obtained from the XRPD
upon heating the samples were recorded for bulk PMOL,
PMOL/S630 and PMOL/EPO binary systems.
Fig. 5. a XRD diffractorams of PMOL and all binary formulations. b VTXRD diffractograms of sono-crystallised PMOL micro/nano crystals. c
VTXRD diffractograms of PMOL/EPO binary systems. d VTXRD diffractograms of PMOL/S630 binary systems
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The single X-ray crystallographic imaging revealed that
the sono-crystallised PMOL existed as monoclinic form (21)
and the details of the crystal structure are depicted in Fig. 4.
The standard XRPD difractogram of the monoclinic sono-
crystallised PMOL form I showed characteristic peaks at 2θ
values at 11.9–26.50 followed by a series less intense peaks at
different 2θ values at ambient temperature (Fig. 5a). Simi-
larly, various drug/polymer binary mixtures showed the
characteristic diffraction peaks of PMOL with slightly lower
intensity indicating that PMOL is present in its same form.
Further analysis via a VTXRPD analysis of crystallised
PMOL clearly showed the characteristic peak of form I at
24.0 degree 2 θ at ambient temperature (24) which started
shifting as the temperature increased. This could be a sign of
the crystalline structural change of the drug (e.g. a distorted
lattice becoming less stable). This alteration of the monoclinic
lattice increases with temperature up to 161°C (Fig. 5b).
Thereafter, a slight temperature increase directed to the
polymorphic transformation of paracetamol to its less stable
form orthorhombic and completed at about 164–166°C
(Fig. 5b). The signature diffraction peak for monoclinic form
at 24.35 2θ shifted to a new position at 24.04 2θ conﬁrming
the transformation of the monoclinic form to less stable form
II.
Similar studies with the formulations with two polymers
showed that regardless of the drug loadings, the signature
peak at 24.36 2θ for monoclinic form starts shifting as a
function of the applying temperature and the transformation
was completed at about 112°C when the peak was positioned
at 24.03 2θ with higher intensity corresponding to the
orthorhombic structure (Fig. 5c). There was no obvious
change observed upon increasing the temperature further
up to 120°C. In contrast, the formulations of PMOL/S630
formulations (F4-F6) exhibited a transformation of PMOL at
slightly higher temperature 120°C (Fig. 5d). This could be
linked to the higher Tg (∼105°C) of S630 polymer which may
have resulted in the thermal stability to retain the crystal
structure of the drug while heating. In the case of EPO, since
the Tg was quite lower (∼48°C), the transformations occurred
at about 112°C. However, the polymorphic transformation
occurring temperature for PMOL depended on the nature
and thermal stability of the polymers used. It can be
concluded that the VTXRPD is a useful tool to study the
temperature effects on the polymorphic transformation (25)
Fig. 5. continued.
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of a crystalline drug. The thermal stability of a crystalline
molecule is pivotal in terms of long-term product stability in
pharmaceutical product manufacturing and development.
CONCLUSIONS
The calculated solubility parameters indicated the
possible drug/polymer miscibility complemented by the
results exhibited by thermal analysis. The approach adopted
by the sono-crystallisation proved to be an effective
technique to produce nano-micro sized crystals with high
thermal stability. The temperature-assisted VTXRPD was
successfully applied to study the alteration in the crystal
structure of the sono-crystallised PMOL from various water
soluble polymer matrices as a function of increasing the
temperature. In this study, it has been seen that the
polymorphic change was temperature dependant (at a range
of 112–120°C) while the nature of the polymers played a
vital role. In conclusion, VTXRPD can effectively be
exploited as a useful approach to study possible polymor-
phic change of various drug candidates to develop different
dosage forms. This is particularly suited to enhance the
dissolution rates of poorly water soluble crystalline drugs or
increasing physical/mechanical properties of various crystal-
line actives, e.g. paracetamol.
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